165 related articles for article (PubMed ID: 12582429)
21. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
Donohue R
Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450
[TBL] [Abstract][Full Text] [Related]
22. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II.
Schiel X; Link H; Maschmeyer G; Glass B; Cornely OA; Buchheidt D; Wilhelm M; Silling G; Helmerking M; Hiddemann W; Ostermann H; Hentrich M
Infection; 2006 Jun; 34(3):118-26. PubMed ID: 16804654
[TBL] [Abstract][Full Text] [Related]
23. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.
Repetto L;
Crit Rev Oncol Hematol; 2009 Nov; 72(2):170-9. PubMed ID: 19406660
[TBL] [Abstract][Full Text] [Related]
24. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
Ghalaut PS; Sen R; Dixit G
J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
[TBL] [Abstract][Full Text] [Related]
25. [Changes in the epidemiology of infections in patients with febrile neutropenia].
Karthaus M; Carratala J
Wien Med Wochenschr; 2001; 151(3-4):47-52. PubMed ID: 11789419
[TBL] [Abstract][Full Text] [Related]
26. The effect of the neutropenic diet in the outpatient setting: a pilot study.
DeMille D; Deming P; Lupinacci P; Jacobs LA
Oncol Nurs Forum; 2006 Nov; 33(2):337-43. PubMed ID: 16518449
[TBL] [Abstract][Full Text] [Related]
27. Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients.
Fleming DR; Ziegler C; Baize T; Mudd L; Goldsmith GH; Herzig RH
Am J Clin Oncol; 2003 Jun; 26(3):285-8. PubMed ID: 12796602
[TBL] [Abstract][Full Text] [Related]
28. [Management of 315neutropenic febrile episodes in a cancer center].
Dutronc H; Billhot M; Dupon M; Eghbali H; Donamaria C; Dauchy FA; Reiffers J
Med Mal Infect; 2009 Jun; 39(6):388-93. PubMed ID: 19062208
[TBL] [Abstract][Full Text] [Related]
29. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
Jaksic B; Martinelli G; Perez-Oteyza J; Hartman CS; Leonard LB; Tack KJ
Clin Infect Dis; 2006 Mar; 42(5):597-607. PubMed ID: 16447103
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
[TBL] [Abstract][Full Text] [Related]
32. [Etiology of febrile neutropenia episodes among cancer patients from Hospital Clinico Universidad Catolica, Santiago-Chile].
Rabagliati B R; Fuentes L G; Orellana U E; Oporto C J; Domínguez M I; Benítez G R; Aedo C I; Ramos G G; Garrido S M; García C P
Rev Chilena Infectol; 2009 Apr; 26(2):106-13. PubMed ID: 19621141
[TBL] [Abstract][Full Text] [Related]
33. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
34. Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy.
Vekemans M; Robinson J; Georgala A; Heymans C; Muanza F; Paesmans M; Klastersky J; Barette M; Meuleman N; Huet F; Calandra T; Costantini S; Ferrant A; Mathissen F; Axelsen M; Marchetti O; Aoun M
Clin Infect Dis; 2007 Jun; 44(12):1593-601. PubMed ID: 17516403
[TBL] [Abstract][Full Text] [Related]
35. Rational selection of patients for antibacterial prophylaxis after chemotherapy.
Cullen MH; Billingham LJ; Gaunt CH; Steven NM
J Clin Oncol; 2007 Oct; 25(30):4821-8. PubMed ID: 17947731
[TBL] [Abstract][Full Text] [Related]
36. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
38. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I.
Mego M; Ebringer L; Drgona L; Mardiak J; Trupl J; Greksak R; Nemova I; Oravcova E; Zajac V; Koza I
Neoplasma; 2005; 52(2):159-64. PubMed ID: 15800715
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies.
Malik I; Hussain M; Yousuf H
J Infect; 2001 Feb; 42(2):120-5. PubMed ID: 11531318
[TBL] [Abstract][Full Text] [Related]
40. Risk index for predicting complications and prognosis in Thai patients with neutropenia and fever.
Chayakulkeeree M; Thamlikitkul V
J Med Assoc Thai; 2003 Mar; 86(3):212-23. PubMed ID: 12757060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
